230
Views
9
CrossRef citations to date
0
Altmetric
Original Articles

Effect of Dietary Cyclic Nigerosylnigerose on Intestinal Immune Functions in Mice

, , , , , , & show all
Pages 2481-2487 | Received 13 Apr 2006, Accepted 10 Jun 2006, Published online: 22 May 2014
 

Abstract

We examined the dietary effects of cyclic nigerosylnigerose (CNN), a dietary indigestible oligosaccharide with four D-glucopyranosyl residues linked by alternating α-(1→3)- and α-(1→6) glucosidic linkages, on the intestinal immune function of mice, and the effects were compared with those of α-(1→3)-linked oligosaccharide (nigerooligosaccharides, NOS) or α-(1→6)-linked oligosaccharide (isomaltooligosaccharides, IMO). BALB/c mice were fed with 1–5% CNN, 5% IMO, or 12.5% NOS for 4 weeks, and the intestinal mucosal immune responses were determined. In the 1–5% CNN fed groups, the amounts of IgA in feces increased significantly. In addition, IgA, transforming growth factor-β1 (TGF-β1), and interleukin-6 (IL-6) secretion by Peyer’s patch (PP) cells were enhanced in CNN fed mice. In the 5% CNN group, pH in the cecum decreased, and the amounts of lactic acid and butyric acid increased. These findings were not observed in the NOS- or IMO-fed group of mice. They suggest that CNN supplementation changes the intestinal environment of microflora and indirectly enhances the immune function in the gut.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.